COMPOUND PROFILE / PEPTIDES & ANALOGUES
TB-500 is a label that requires molecular clarification. An analytical paper identified an acetylated thymosin beta-4 fragment in one tested product; this must not be treated as interchangeable with evidence for full-length thymosin beta-4 formulations.
Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.
Focused editorial source update: 20 October 2026. Primary records linked; abstract/label scope disclosed. No independent clinical review claimed.
Confirm exact identity, sequence, alias or formulation before attaching product-specific evidence.
TB-500 is a label that requires molecular clarification. An analytical paper identified an acetylated thymosin beta-4 fragment in one tested product; this must not be treated as interchangeable with evidence for full-length thymosin beta-4 formulations.
Identity comes before a mechanism claim. The 2012 analytical investigation identified Ac-LKKTETQ in the tested material. Evidence attached to a different sequence or modification cannot simply be reassigned to it.
The linked phase 2 thymosin beta-4 ophthalmic trial concerned an eye formulation in people with dry eye. Its primary endpoints did not significantly differ between groups, while some secondary outcomes did. This neither establishes musculoskeletal recovery from an injected fragment nor validates a product described only as TB-500.
Studies using full-length thymosin beta-4 and studies using fragments must be separated. A common label or related sequence does not establish equal exposure, activity or clinical effect. This profile does not merge all thymosin-related findings into one treatment claim.
The analytical identification study is not a human safety study. Ophthalmic clinical observations cannot establish injectable-fragment safety. Unresolved identity and sample provenance are additional limitations that should remain visible in a report or research summary.
FDA July 2026 advisory materials discuss TB-500-related bulk substances. That process is distinct from approval of a medicine. A precise current product/jurisdiction status requires its own regulator check; this page is not a worldwide legality statement.
No established general human dosing schedule for a material labelled only TB-500 follows from these sources. Do not combine a fragment identification with a different full-length study to construct a protocol.
The supplied TB-500 / Thymosin Beta-4 fragment profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.
Follow the cited records and registered research. Profiles remain research drafts.